<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Biomarin Pharmaceutical Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/biomarin-pharmaceutical-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Mon, 21 May 2012 16:42:30 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(MYGN) Myriad Inks Deal with Cephalon</title>
		<link>http://www.stockbloghub.com/2012/04/04/mygn-myriad-inks-deal-with-cephalon/97439</link>
		<comments>http://www.stockbloghub.com/2012/04/04/mygn-myriad-inks-deal-with-cephalon/97439#comments</comments>
		<pubDate>Wed, 04 Apr 2012 16:53:51 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=97439</guid>
		<description><![CDATA[The recent agreement with Cephalon is another attempt by Myriad Genetics (MYGN) to establish itself as a strong player in the companion diagnostic market. Cephalon is a subsidiary of Teva Pharmaceuticals (TEVA).  Under the agreement, Myriad will conduct BRCA1 and BRCA2 mutation testing on patients with Bracanalysis before being enrolled in a phase I/II clinical study. Over the recent past, the company has entered into similar agreements with players such as Abbott (ABT), Astra Zeneca (AZN) and BioMarin Pharmaceuticals (BMRN) to provide companion diagnostic tests for clinical trial enrollment. Bracanalysis is Myriad’s flagship product, which analyzes the BRCA1 and BRCA2 genes to assess a woman&#8217;s risk for hereditary breast and ovarian cancer. Moreover, the acquisition of RBM (Rules-Based Medicine), made in 2011 would better place Myriad in this arena on ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/04/04/mygn-myriad-inks-deal-with-cephalon/97439/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(QGEN) Qiagen Expands with New Deals</title>
		<link>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111</link>
		<comments>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111#comments</comments>
		<pubDate>Fri, 13 Jan 2012 21:09:44 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[Alaska Air Group Inc.]]></category>
		<category><![CDATA[ALK]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[Laboratory Corporation of America Holdings]]></category>
		<category><![CDATA[LH]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[QGEN]]></category>
		<category><![CDATA[Qiagen NV]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=90111</guid>
		<description><![CDATA[In an attempt to expand its companion diagnostic portfolio for several types of new anti-cancer drugs, Qiagen (QGEN) recently entered into two different agreements with US biotech companies, namely Insight Genetics, Inc. and Personal Genome Diagnostics Inc. Through the agreement, the company seeks to obtain worldwide exclusive rights for biomarkers for gene mutation. In collaboration with the Tennessee-based molecular diagnostics company Insight Genetics, Qiagen will provide a genetic test with a biomarker for non-small cell lung cancers (NSCLC) that express the abnormal anaplastic lymphoma kinase (ALK) gene. Meanwhile, under the agreement with Maryland-based Personal Genome Diagnostics, Qiagen’s 89% subsidiary Ipsogen obtained rights to genetic testing for mutations of the IDH1 and IDH2 genes for brain cancers, acute myelogenous leukemia (AML) and other malignancies. With the companion diagnostics market expected to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2012/01/13/qgen-qiagen-expands-with-new-deals/90111/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMRN) BioMarin Pharmaceutical Reports Pipeline Progress</title>
		<link>http://www.stockbloghub.com/2011/12/14/bmrn-biomarin-pharmaceutical-reports-pipeline-progress/87928</link>
		<comments>http://www.stockbloghub.com/2011/12/14/bmrn-biomarin-pharmaceutical-reports-pipeline-progress/87928#comments</comments>
		<pubDate>Wed, 14 Dec 2011 20:17:36 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=87928</guid>
		<description><![CDATA[Recently, BioMarin Pharmaceutical Inc. (BMRN) commenced a mid-stage study of its pipeline candidate GALNS (N-acetylgalactosamine 6-sulfatase) in children suffering from mucopolysaccharidosis IVA (MPS IVA), a rare genetic enzyme deficiency disorder. The company intends to evaluate the safety and tolerability of the drug dosed at 2.0 mg/kg/week over a period of one year. The study will evaluate 10 to 15 children below 5 years of age. The open-label, multinational study will also evaluate the levels of urinary keratan sulfate (KS) and growth velocity. Apart from the mid-stage study in children, GALNS is also being evaluated in a randomized, double-blind, placebo-controlled late-stage study (n~160) in the MPS IVA indication. BioMarin is enrolling patients in a late stage study with primary endpoint of six-minute walk distance. Enrollment is underway in the 24-week study. ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/12/14/bmrn-biomarin-pharmaceutical-reports-pipeline-progress/87928/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMRN) BioMarin Pharmaceutical to Buy Pfizer Plant</title>
		<link>http://www.stockbloghub.com/2011/06/29/bmrn-biomarin-pharmaceutical-to-buy-pfizer-plant/77641</link>
		<comments>http://www.stockbloghub.com/2011/06/29/bmrn-biomarin-pharmaceutical-to-buy-pfizer-plant/77641#comments</comments>
		<pubDate>Wed, 29 Jun 2011 17:04:31 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77641</guid>
		<description><![CDATA[BioMarin Pharmaceutical Inc. (BMRN) recently announced that it will acquire an integrated biologics manufacturing plant from pharma giant Pfizer Inc. (PFE) which will expand its manufacturing capacity to manage its proliferating product portfolio and its maturing pipeline. The plant, for which BioMarin will pay $48.5 million, is located in Shanbally, Cork, Ireland and is spread across 133,000 square feet. The purchase price is almost five times less than the cost of building a new facility. BioMarin is expected to close the deal in the third quarter of 2011. Moreover, BioMarin will have to spend approximately $4 million annually to maintain the facility. The current manufacturing facilities have the capacity to manufacture protein products worth roughly $1 billion in revenue. With a maturing pipeline, the company will need additional resources to ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/bmrn-biomarin-pharmaceutical-to-buy-pfizer-plant/77641/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMRN) BioMarin Pharmaceutical &#8211; Bear of the Day</title>
		<link>http://www.stockbloghub.com/2011/04/27/bmrn-biomarin-pharmaceutical-bear-of-the-day/72524</link>
		<comments>http://www.stockbloghub.com/2011/04/27/bmrn-biomarin-pharmaceutical-bear-of-the-day/72524#comments</comments>
		<pubDate>Wed, 27 Apr 2011 15:53:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=72524</guid>
		<description><![CDATA[We are downgrading BioMarin Pharmaceutical Inc. (BMRN) to Underperform from Neutral following the below-par showing of the company in the final quarter of 2010. Earnings were hurt by lower-than-expected revenues. We were disappointed with the continued weak performance of Aldurazyme and the slow Firdapse ramp. Moreover, we expect cash burn to increase since the company is investing heavily in its pipeline. Any negative news regarding the pipeline would have an adverse impact on the stock. The early/mid-stage pipeline at BioMarin also concerns us. These headwinds cause us to believe that there is little reason for investors to own the stock at current levels. Our target price is $24.00. BIOMARIN PHARMA (BMRN): Free Stock Analysis Report Zacks Investment Research]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/27/bmrn-biomarin-pharmaceutical-bear-of-the-day/72524/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYGN) Myriad Genetics and BioMarin Pharmaceuticals Enter Agreement for Testing</title>
		<link>http://www.stockbloghub.com/2011/04/09/mygn-myriad-genetics-and-biomarin-pharmaceuticals-enter-agreement-for-testing/70983</link>
		<comments>http://www.stockbloghub.com/2011/04/09/mygn-myriad-genetics-and-biomarin-pharmaceuticals-enter-agreement-for-testing/70983#comments</comments>
		<pubDate>Sat, 09 Apr 2011 19:13:47 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diagnostic Substances]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Abbott Laboratories]]></category>
		<category><![CDATA[ABT]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[MYGN]]></category>
		<category><![CDATA[Myriad Genetics Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70983</guid>
		<description><![CDATA[Myriad Genetics (MYGN) has entered into an agreement with BioMarin Pharmaceuticals (BMRN) to conduct BRCA1 and BRCA2 mutation testing on patients to be enrolled in the latter’s phase I/II clinical study of BMN 673. BMN 673 is a PARP-inhibitor drug candidate for treatment of genetically defined cancers. Bracanalysisis Myriad’s flagship product, contributing 89% of total revenue. This test provides a comprehensive analysis of BRCA1 and BRCA2 genes for assessing woman&#8217;s risk of hereditary breast and ovarian cancers. Under the agreement, the company will carry out Bracanalysis test to identify the presence of germline mutations in the patients prior to enrollment in the study. Accordingly, it will provide standard test reports to the clinicians. Myriad is aiming at establishing itself as a strong player in the companion diagnostic market. To establish ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/09/mygn-myriad-genetics-and-biomarin-pharmaceuticals-enter-agreement-for-testing/70983/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Pharma Merger Mania is Heating Up</title>
		<link>http://www.stockbloghub.com/2010/07/31/mrk-pharma-merger-mania-is-heating-up/45477</link>
		<comments>http://www.stockbloghub.com/2010/07/31/mrk-pharma-merger-mania-is-heating-up/45477#comments</comments>
		<pubDate>Sat, 31 Jul 2010 16:17:01 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45477</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, July 28, 2010: Issue #1311 In the cellphone world, it’s all about “apps.” In the oil and natural gas industries, it’s all about supplies. And in the healthcare sector, it’s all about pills. Lots and lots of pills. Blue pills, purple pills, sleeping pills, anti-depressants. They’re everywhere. It’s big business for Big Pharma and the companies are very good at marketing their products. Comedian Chris Rock referred to this trend, noting that drug companies keep naming symptoms until they find one that you have: Are you sad, are you lonely, are you hot, are you cold? You gotta take this pill! And they don’t even tell you what the pill does… they just keep naming symptoms. I saw a commercial the other day that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/31/mrk-pharma-merger-mania-is-heating-up/45477/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MRK) Big Pharma Has a Big Problem and Merger Mania is Heating Up</title>
		<link>http://www.stockbloghub.com/2010/07/28/mrk-big-pharma-has-a-big-problem-and-merger-mania-is-heating-up/45107</link>
		<comments>http://www.stockbloghub.com/2010/07/28/mrk-big-pharma-has-a-big-problem-and-merger-mania-is-heating-up/45107#comments</comments>
		<pubDate>Wed, 28 Jul 2010 18:53:53 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Drug Manufacturers - Major]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[Glaxosmithkline plc]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=45107</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, July 28, 2010: Issue #1311 In the cellphone world, it’s all about “apps.” In the oil and natural gas industries, it’s all about supplies. And in the healthcare sector, it’s all about pills. Lots and lots of pills. Blue pills, purple pills, sleeping pills, anti-depressants. They’re everywhere. It’s big business for Big Pharma and the companies are very good at marketing their products. Comedian Chris Rock referred to this trend, noting that drug companies keep naming symptoms until they find one that you have: Are you sad, are you lonely, are you hot, are you cold? You gotta take this pill! And they don’t even tell you what the pill does… they just keep naming symptoms. I saw a commercial the other day that ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/07/28/mrk-big-pharma-has-a-big-problem-and-merger-mania-is-heating-up/45107/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMRN) BioMarin Pharma Announces Good News</title>
		<link>http://www.stockbloghub.com/2010/04/22/bmrn-biomarin-pharma-announces-good-news/34614</link>
		<comments>http://www.stockbloghub.com/2010/04/22/bmrn-biomarin-pharma-announces-good-news/34614#comments</comments>
		<pubDate>Thu, 22 Apr 2010 20:03:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=34614</guid>
		<description><![CDATA[BioMarin Pharma Inc. (BMRN) announced recently that its product Firdapse (Amifampridine phosphate) for treating Lambert Eaton Myasthenic Syndrome (LEMS) is commercially available in the European Union. While the company has launched the product in Germany and the UK subsequent launches in other major European markets are expected by the end of the year. The LEMS drug received marketing approval from the European Commission in Dec 2009. Firdapse is the first drug to hit the European market for treating the rare autoimmune disease. Firdapse enjoys orphan drug status and 10 years of market exclusivity in Europe. The drug has also been granted an orphan drug designation by the US Food and Drug Administration (FDA). The drug has the potential to be used for other indications as well Incorporatedluding multiple sclerosis (MS). ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/04/22/bmrn-biomarin-pharma-announces-good-news/34614/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMRN) BioMarin Pharmaceutical&#8217;s Earnings Top Analyst Estimates</title>
		<link>http://www.stockbloghub.com/2010/02/24/bmrn-biomarin-pharmaceuticals-earnings-top-analyst-estimates/28892</link>
		<comments>http://www.stockbloghub.com/2010/02/24/bmrn-biomarin-pharmaceuticals-earnings-top-analyst-estimates/28892#comments</comments>
		<pubDate>Wed, 24 Feb 2010 18:54:05 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[GENZ]]></category>
		<category><![CDATA[Genzyme Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28892</guid>
		<description><![CDATA[BioMarin Pharmaceutical Inc. (BMRN) reported fourth-quarter 2009 earnings of 13 cents per share (excluding special items), beating the Zacks Consensus Estimate of break-even earnings. The company had earned 8 cents (excluding special items) in the year-ago quarter. Quarterly Results Revenue for the reported quarter came in at $87.1 million as against $99.3 million in the comparable quarter last year, down 14%. Total net product revenues increased to $83.9 million from $65.9 million in the fourth quarter of 2008. Royalty and license revenues in the quarter came in at $2.8 million as against $1.8 million in the year-ago quarter. Revenue from collaborative agreements accounted for the remaining total revenue in the reported quarter. Revenue from Naglazyme came in at $44.4 million in the reported quarter as against $36.5 million in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/24/bmrn-biomarin-pharmaceuticals-earnings-top-analyst-estimates/28892/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMRN) BioMarin Pharmaceutical Announces Plan to Expand</title>
		<link>http://www.stockbloghub.com/2010/02/09/bmrn-biomarin-pharmaceutical-announces-plan-to-expand/27465</link>
		<comments>http://www.stockbloghub.com/2010/02/09/bmrn-biomarin-pharmaceutical-announces-plan-to-expand/27465#comments</comments>
		<pubDate>Tue, 09 Feb 2010 21:33:38 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=27465</guid>
		<description><![CDATA[BioMarin Pharmaceutical Inc. (BMRN) announced recently that it will purchase the privately-held drug discovery and early stage development company LEAD Therapeutics. LEAD is developing LT-673, an orally available poly (ADP-ribose) polymerase (PARP) inhibitor for treating patients suffering from rare, genetically defined cancers. The stock purchase agreement requires BioMarin to make an upfront payment of $18 million to the shareholders of the private company. The acquisition would add LT-673 to BioMarin’s pipeline. BioMarin intends to submit an Investigational New Drug (IND) application with the Food and Drug Administration (FDA) by the end of 2010. BioMarin will pay LEAD another $11 million on acceptance of the application which would enable LT-673 to be tested on humans. Furthermore, BioMarin will pay up to $68 million more in the event of the drug clearing ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/09/bmrn-biomarin-pharmaceutical-announces-plan-to-expand/27465/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMRN) BioMarin Pharma&#8217;s Drug Cleared in Europe</title>
		<link>http://www.stockbloghub.com/2010/01/06/bmrn-biomarin-pharmas-drug-cleared-in-europe/24317</link>
		<comments>http://www.stockbloghub.com/2010/01/06/bmrn-biomarin-pharmas-drug-cleared-in-europe/24317#comments</comments>
		<pubDate>Thu, 07 Jan 2010 00:05:46 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=24317</guid>
		<description><![CDATA[BioMarin Pharma Inc. (BMRN) announced recently that its drug candidate 3, 4-diaminopyridine amifampridine phosphate (3,4-DAP), indicated for treating Lambert Eaton Myasthenic Syndrome (LEMS), has received marketing approval from the European Commission. In October 2009, the Committee for Medicinal Products for Human Use of the European Medicines Evaluations Agency gave a positive opinion and recommended the approval of amifampridine phosphate for LEMS. Amifampridine phosphate is the first drug to hit the market for treating the rare autoimmune disease. The drug enjoys orphan drug status and 10 years of market exclusivity in Europe. Amifampridine phosphate has also been granted an orphan drug designation by the U.S. Food and Drug Administration (FDA). BioMarin intends to launch amifampridine in the European Union in mid-March. Furthermore, the company is looking to develop an appropriate strategy ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/01/06/bmrn-biomarin-pharmas-drug-cleared-in-europe/24317/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMRN) BioMarin Pharmaceutical Earns Orphan Status From FDA</title>
		<link>http://www.stockbloghub.com/2009/12/02/bmrn-biomarin-pharmaceutical-earns-orphan-status-from-fda/21751</link>
		<comments>http://www.stockbloghub.com/2009/12/02/bmrn-biomarin-pharmaceutical-earns-orphan-status-from-fda/21751#comments</comments>
		<pubDate>Wed, 02 Dec 2009 20:18:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[EC]]></category>
		<category><![CDATA[Ecopetrol Sa]]></category>
		<category><![CDATA[Morgan Stanley]]></category>
		<category><![CDATA[MS]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21751</guid>
		<description><![CDATA[Recently, BioMarin Pharmaceutical Inc. (BMRN) announced that the U.S. Food and Drug Administration (FDA) granted orphan drug status to its candidate 3,4-diaminopyridine amifampridine phosphate (3,4-DAP), for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). As a reminder, BioMarin acquired the privately held Huxley Pharmaceuticals Inc. last month which possessed rights to a proprietary form of 3, 4-diaminopyridine amifampridine phosphate for LEMS treatment. In October 2009, the Committee for Medicinal Products for Human Use of the European Medicines Evaluations Agency gave a positive opinion and recommended the approval of amifampridine phosphate for LEMS. The European Commission (EC) is expected to deliver its decision regarding the approvability of the candidate in late 2009 or early 2010.BioMarin intends to launch the drug in Europe in the first quarter of 2010 and is looking ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/02/bmrn-biomarin-pharmaceutical-earns-orphan-status-from-fda/21751/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ASH) Investing in the Biotech Sector: Here’s An Easy Way to Profit from Biotech Stocks</title>
		<link>http://www.stockbloghub.com/2009/11/11/ash-investing-in-the-biotech-sector-here%e2%80%99s-an-easy-way-to-profit-from-biotech-stocks/20305</link>
		<comments>http://www.stockbloghub.com/2009/11/11/ash-investing-in-the-biotech-sector-here%e2%80%99s-an-easy-way-to-profit-from-biotech-stocks/20305#comments</comments>
		<pubDate>Wed, 11 Nov 2009 21:51:36 +0000</pubDate>
		<dc:creator>InvestmentU</dc:creator>
				<category><![CDATA[Basic Materials]]></category>
		<category><![CDATA[Chemicals - Major Diversified]]></category>
		<category><![CDATA[ARIA]]></category>
		<category><![CDATA[Ariad Pharmaceuticals Inc]]></category>
		<category><![CDATA[ASH]]></category>
		<category><![CDATA[Ashland Inc.]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>
		<category><![CDATA[CELG]]></category>
		<category><![CDATA[Celgene Corporation]]></category>
		<category><![CDATA[IMGN]]></category>
		<category><![CDATA[Immunogen Inc]]></category>
		<category><![CDATA[JPM]]></category>
		<category><![CDATA[JPMorgan Chase & Company]]></category>
		<category><![CDATA[PARD]]></category>
		<category><![CDATA[Poniard Pharmaceuticals Inc]]></category>
		<category><![CDATA[SuperGen Inc]]></category>
		<category><![CDATA[SUPG]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=20305</guid>
		<description><![CDATA[by Marc Lichtenfeld, Healthcare Expert Wednesday, November 11, 2009: Issue #1135 Investing in the biotech sector can be risky – no doubt about that. But you know what? There are a lot of ways to make money from biotech stocks, too. If you know what to look for, that is. Two obvious examples include: Picking the company behind the next breakthrough drug for cancer or Alzheimer’s. Digging out companies that are likely takeover targets (something my colleague Louis Basenese does expertly in his Takeover Trader service), or landing lucrative drug partnership deals, which send the stocks higher. But there’s another excellent way that shorter-term investors can grab gains and profit from biotech sector… Follow the Biotech Sector Conference Buzz Throughout the year, the biotech sector holds many key conferences where ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/11/ash-investing-in-the-biotech-sector-here%e2%80%99s-an-easy-way-to-profit-from-biotech-stocks/20305/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMRN) BioMarin Pharmaceutical Purchases Huxley Pharmaceuticals</title>
		<link>http://www.stockbloghub.com/2009/10/27/bmrn-biomarin-pharmaceutical-purchases-huxley-pharmaceuticals/18932</link>
		<comments>http://www.stockbloghub.com/2009/10/27/bmrn-biomarin-pharmaceutical-purchases-huxley-pharmaceuticals/18932#comments</comments>
		<pubDate>Wed, 28 Oct 2009 01:37:45 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[BIIB]]></category>
		<category><![CDATA[Biogen Idec Inc]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[PFE]]></category>
		<category><![CDATA[Pfizer Inc.]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=18932</guid>
		<description><![CDATA[Recently, BioMarin Pharmaceutical Inc. (BMRN) announced that it has acquired the privately held Huxley Pharmaceuticals Inc., which possessed rights to a proprietary form of 3,4-diaminopyridine amifampridine phosphate ( 3,4-DAP), for the treatment of Lambert Eaton Myasthenic Syndrome (LEMS). Under the terms of the transaction, BioMarin has already made an upfront payment of $15 million to Huxley shareholders and will pay an additional $7.5 million upon the final approval of amifampridine for LEMS from the European Commission [EC]. The EC is expected to grant its approval in late 2009 or early 2010. Furthermore, Huxley stockholders would receive up to approximately $36 million in milestone payments if certain sales and U.S. development milestones are met. BioMarin intends to launch amifampridine phosphate in Europe in the first quarter and is looking to develop ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/10/27/bmrn-biomarin-pharmaceutical-purchases-huxley-pharmaceuticals/18932/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(BMRN) BioMarin Pharmaceutical Begins Mid-Stage Trial</title>
		<link>http://www.stockbloghub.com/2009/09/23/bmrn-biomarin-pharmaceutical-begins-mid-stage-trial/15916</link>
		<comments>http://www.stockbloghub.com/2009/09/23/bmrn-biomarin-pharmaceutical-begins-mid-stage-trial/15916#comments</comments>
		<pubDate>Wed, 23 Sep 2009 19:42:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ALTU]]></category>
		<category><![CDATA[Altus Pharmaceuticals Inc]]></category>
		<category><![CDATA[Biomarin Pharmaceutical Inc]]></category>
		<category><![CDATA[BMRN]]></category>
		<category><![CDATA[ENZN]]></category>
		<category><![CDATA[Enzon Pharmaceuticals Inc]]></category>
		<category><![CDATA[Merck & Company Inc.]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Shire Limited]]></category>
		<category><![CDATA[SHPGY]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=15916</guid>
		<description><![CDATA[Yesterday, BioMarin Pharmaceutical Inc. (BMRN) said it started a mid-stage study of PEG-PAL for the treatment of phenylketonuria (PKU). The company expects initial results from the study in mid-2010. It is co-developing the candidate with Merck Serono (MRK). The primary objective of the open-label, multi-center study, to be conducted in up to 35 patients, is to evaluate the effect of PEG-PAL on blood phenylalanine (Phe) concentrations in PKU patients. The secondary objectives are to evaluate its safety and tolerability, immune response and steady state pharmacokinetics of subcutaneous injections of multiple dose levels. BioMarin, which competes with companies such as Enzon Pharmaceuticals Inc. (ENZN), Shire Plc (SHPGY) and Altus Pharmaceuticals Inc. (ALTU), already has Kuvan in the market for treating PKU. The primary difference between PEG-PAL and Kuvan is the mode ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/09/23/bmrn-biomarin-pharmaceutical-begins-mid-stage-trial/15916/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

